Alarm over pregabalin script blowout

The Pharmaceutical Benefits Advisory Committee is investigating the inappropriate prescribing of pregabalin after a blowout in scripts, costing over $100 million to date.

Pregabalin (Lyrica) was listed on the PBS for neuropathic pain in March 2013, which the PBAC drug utilisation sub-committee (DUSC) estimated would benefit over 200,000 people.

However, more than 433